Unlocking
the future
of medicine

About us

Offering an unrivalled modular platform and tailored hyper-targeting is how we stand apart

Pipeline

Reducing the impact of cancer and autoimmune diseases on people’s lives is why we’re here

Research and development

Pushing the boundaries of human advancement in medicine is what drives us every day

Investors
 
 
 

An immunotherapy platform that unlocks unlimited possibilities for the future of medicine

The Nykode Therapeutics platform is built around the Vaccibody molecule. Inducing fast, strong and long-lasting immune responses, and demonstrating a positive safety profile, our pioneering Vaccibody™ immunotherapy has the potential to treat many disease areas, including cancer.

Highlights

Nykode Therapeutics to Present Interim Data from the VB-C-03 ...

Read More
19 December 2025

Nykode Therapeutics Strengthens Board with the Nomination of Dr. ...

Read More
18 December 2025

Nykode Therapeutics ASA – Notice of Extraordinary General Meeting

Read More
18 December 2025

Nykode Therapeutics reports Q3 2025 Financial Results

Read More
24 November 2025

Nykode Therapeutics – Invitation to Q3 2025 Financial Results ...

Read More
13 November 2025

Nykode Therapeutics to Present Data on the Strength of ...

Read More
05 November 2025

Nykode Therapeutics Strengthens Intellectual Property Portfolio with New U.S. ...

Read More
04 November 2025

Nykode Announces Updated Strategy to Increase Value for Patients ...

Read More
27 August 2025

Nykode Therapeutics reports Q2 2025 Financial Results

Read More
27 August 2025